| 892.87 -4.98 (-0.55%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1141.14 | 1-year : | 1332.86 |
| Resists | First : | 977.01 | Second : | 1141.14 |
| Pivot price | 857.85  |
|||
| Supports | First : | 860.03 | Second : | 787.72 |
| MAs | MA(5) : | 886.85 |
MA(20) : | 864.16  |
| MA(100) : | 917.34 |
MA(250) : | 857.1 |
|
| MACD | MACD : | -11.4 |
Signal : | -21 |
| %K %D | K(14,3) : | 88.8 |
D(3) : | 80.3 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 1072.75 | Low : | 661.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARGX ] has closed below upper band by 23.0%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 916.57 - 921.25 | 921.25 - 924.84 |
| Low: | 879.18 - 884.07 | 884.07 - 887.81 |
| Close: | 885.19 - 893.33 | 893.33 - 899.57 |
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Sat, 31 Oct 2026
argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance Singapore
Sat, 31 Oct 2026
argenx SE (ARGX.BR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 30 Oct 2026
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 28 Oct 2026
Argenx SE : Jefferies gives a Buy rating - marketscreener.com
Tue, 27 Oct 2026
argenx SE American Depositary Shares (ARGX) Stock Price: Oct 26 Close $869.33 - Gotrade
Mon, 26 Oct 2026
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Boston Scientific (BSX) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 1,560 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 46.1 (%) |
| Shares Short | 1,350 (K) |
| Shares Short P.Month | 1,260 (K) |
| EPS | 28.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.38 |
| Profit Margin | 31.7 % |
| Operating Margin | 36.2 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 52 % |
| Gross Profit (p.s.) | 56.28 |
| Sales Per Share | 94.13 |
| EBITDA (p.s.) | 30.21 |
| Qtrly Earnings Growth | 50.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 30.92 |
| PEG Ratio | 1 |
| Price to Book value | 165.96 |
| Price to Sales | 9.48 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|